About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68827 record(s)
Req # A-2023-001031
Adverse Drug Reactions (ADRs) for ONDANSETRON. Report numbers: 001051602, E2B_06544200, E2B_06544246, E2B_06549302, E2B_06549717, E2B_06550996, E2B_06559699, E2B_06566386. ADRs for LANSOPRAZOLE. Report numbers: E2B_06560926, 001057449.Organization: Health Canada
March 2024
Req # A-2023-001035
Adverse Drug Reactions (ADRs). Report numbers: E2B_06586522, E2B_06577728, 001058691, 001058257, E2B_06425916, E2B_05046859.Organization: Health Canada
March 2024
Req # A-2023-001042
Adverse Drug Reactions (ADRs) for EMEND. Report numbers: 000921572, 000926951, 000929133, 000930002. ADRs for EMEND IV. Report numbers: E2B_03477895, E2B_02336796, 000725466, 000732475.Organization: Health Canada
March 2024
Req # A-2023-001077
Adverse Drug Reactions (ADRs). Report numbers: E2B_06553666, 001060638, 001062401, E2B_00146713, 001057489, 01051366, E2B_06566392, 001051594, 001051599, 01050689.Organization: Health Canada
March 2024
Req # A-2023-001094
Adverse Drug Reactions (ADRs) for EMEND IV. Report numbers: E2B_02534490, E2B_00236901, 000948750. ADR for INTEGRILIN. Report number: E2B_03438497. ADRs for INTRON A. Report numbers: 000928459, 000945380. ADRs for INVANZ. Report numbers:…Organization: Health Canada
March 2024
Req # A-2023-001099
Adverse Drug Reaction (ADR). Report number: E2B_06560988.Organization: Health Canada
March 2024
Req # A-2023-001107
Adverse Drug Reactions (ADRs). Report numbers: E2B_06466620, E2B_06511006, E2B_06434936, E2B_06463521, E2B_06463677.Organization: Health Canada
March 2024
Req # A-2023-001146
Adverse Drug Reactions (ADRs). Report numbers: E2B_06575846, E2B_02988422, E2B_06641534, E2B_06644226.Organization: Health Canada
March 2024
Req # A-2023-001148
Adverse Drug Reactions (ADRs) for Dexilant. Report numbers: 001062510. ADR for Ixazomib. Report number: E2B_06626740. ADR for Pantoprazole sodium. Report number: E2B_06587978. ADR for Tecta. Report number: 1055931. ADR for ADDERALL XR. Report number…Organization: Health Canada
March 2024
Req # A-2023-001161
Adverse Drug Reactions (ADRs). Report numbers: E2B_06600971, E2B_06600988 , 001056382 , 001055429 , E2B_06617133, E2B_06646470.Organization: Health Canada
March 2024